默沙东被低估的“王牌”？“坏胆固醇”克星催生百亿美元规模市场

Core Viewpoint - Merck's new oral lipid-lowering drug has shown significant efficacy in reducing low-density lipoprotein cholesterol (LDL-C) in a late-stage head-to-head clinical trial, addressing a critical health issue linked to various chronic diseases [3][4]. Group 1: Clinical Data and Drug Efficacy - The new drug, enlicitide decanoate, targets the PCSK9 protein, which plays a key role in cholesterol regulation, and has demonstrated a reduction of LDL-C levels by up to 64.6% compared to baseline in patients already on statin therapy [4]. - In head-to-head comparisons, enlicitide reduced LDL-C levels by 56.7% compared to bempedoic acid and by 36% compared to ezetimibe [4]. - High LDL-C levels are associated with a 6.4 times increased risk of chronic disease mortality and accelerate atherosclerosis, leading to a 20%-30% increase in coronary heart disease risk [3]. Group 2: Market Potential and Competitive Landscape - Analysts from Scotiabank estimate that enlicitide could be one of Merck's most undervalued pipeline assets, with peak sales potential reaching several billion dollars [4]. - The drug has received priority review status from the FDA and is expected to be approved as early as this year [4]. - AstraZeneca is also developing a PCSK9 oral lipid-lowering drug that can reduce LDL-C levels by nearly 51%, indicating strong competition in the market [5]. Group 3: Industry Trends and Future Outlook - The demand for PCSK9 inhibitors is increasing, with various new formulations being developed, including a semi-annual injection by Novartis, but no oral formulations have been approved yet [5]. - Goldman Sachs projects that oral therapies could drive sales of PCSK9 drugs to approximately $12 billion by 2034, up from around $4 billion last year [6].